ALK inhibitors are effective in the treatment of inflammatory myofibroblastic tumor, non-small-cell lung cancer with ALK rearrangement and ALK-positive ALCL [90,91], and represent a therapeutic option for ALK-positive LBCL [92,93]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.